Case Report: Balancing immune responses – multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma

BackgroundCombination treatment with BRAF/MEK inhibitors favorably impact progression-free survival in malignant melanoma. However, it may cause paradoxical activation of the MAPK/ERK pathway in immune cells without BRAF mutation, which may lead to over activation of the immune system, especially in...

Descrición completa

Detalles Bibliográficos

Principais autores:	Katrin Pape, Maria Protopapa, Muriel Schraad, Falk Steffen, Frauke Zipp, Stefan Bittner
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2023-11-01
Series:	Frontiers in Oncology
Assuntos:	malignant melanoma BRAF/MEK treatment multiple sclerosis B cell depletion ocrelizumab multi-color flow cytometry
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1303141/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!